tirzepatide farmaco italia Mounjaro, il contro l'obesità arriva in Il farmaco per il diabete

Realworld weightloss effectiveness of glucagonlike peptide1 agonists among patients with type 2 diabetes: A retrospective cohort study

3 Are weight-loss injections addictive

Role of a dual glucose-dependent insulinotropic peptide (GIP)/glucagon-like peptide-1 receptor agonist (twincretin) in glycemic control: From pathophysiology to treatment

However, it's important to note that tirzepatide is not FDA-approved for the treatment of MASLD or MASH, and any such use would be considered off-label

Researchers discovered its remarkable weight loss effects during clinical trials, leading to its approval specifically for obesity treatment under the brand name Zepbound

This dual-action mechanism helps lower blood sugar levels and control appetite